Tasso Partners Leads $26M Series B for Amplifica's Injectable Hair-Growth Pipeline

Amplifica Holdings Group has closed an oversubscribed $26M Series B Preferred Stock financing to advance its injectable pipeline for androgenetic alopecia, the company announced on August 12, 2026. Tasso Partners, LLC led the round, with participation from Eli Lilly and Company, principals of Scopia Capital Management, LP, and other new and existing investors.

The San Diego-area clinical-stage biotech is developing signaling molecules designed to reactivate dormant hair follicles — a strategy it frames as distinct from another cosmetic workaround for hair loss. Amplifica said the proceeds will support continued clinical development of its injectable product candidates. It did not disclose a valuation, ownership terms, a program-by-program budget, or the identities of every investor in the syndicate.

The new financing follows an $11.8M Series A announced in October 2022. The two publicly announced priced rounds total at least $37.8M, though Amplifica did not state an official cumulative funding figure in the latest release — a distinction that matters in private-company reporting, where simple arithmetic is not the same as a complete financing history.

Amplifica's official pipeline lists AMP-303, AMP-203/AMP-506, and AMP-601 across four differentiated programs. The company says the candidates act through distinct and complementary mechanisms, giving it multiple clinical paths rather than forcing a single molecule to carry the thesis. The financing release does not identify the molecular composition of each candidate, so the platform is best understood at the mechanism level.

The company grew out of regenerative-biology research associated with co-founder and CSO Maksim Plikus, PhD, a professor at the University of California, Irvine. UC Irvine's account of the science traces Amplifica to observations about naturally occurring signals that can activate hair-follicle stem cells, including work on mechanisms involving SCUBE3 and osteopontin.

Amplifica has reported early proof-of-concept human data for lead candidate AMP-303. In 2025, the company said first-in-human results would be presented at the Society for Investigative Dermatology annual meeting, and UC Irvine described measurable hair-regrowth improvements after one treatment cycle. That is a useful signal, not a regulatory finish line: the Series B gives Amplifica capacity to test safety, efficacy, dosing, durability, and candidate selection through further clinical development.

Commercially, Amplifica cites more than 50 million men and 30 million women in the United States affected by androgenetic alopecia, and estimates a market opportunity above $6B. Current daily-use options such as finasteride and minoxidil help some patients, but Amplifica argues that adherence, tolerability, side effects, limited efficacy, and limited applicability in women leave room for new approaches.